Browsing by Author "Peralta, Mirta"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort
    (2020) Ridruejo, Ezequiel; Piñero, Federico; Mendizabal, Manuel; Cheinquer, Hugo; Soza, Alejandro; Herz Wolff, Fernando; Anders, Margarita; Reggiardo, Virginia; Ameigeiras, Beatriz; Palazzo, Ana; Alonso, Cristina; Schinoni, María Isabel; Videla Zuain, María Grazia; Tanno, Federico; Figueroa, Sebastián; Santos, Luisa; Peralta, Mirta; Vistarini, Cecilia; Adrover, Raúl; Fernández, Nora
  • No Thumbnail Available
    Item
    Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network
    (2022) Bessone, Fernando; Garcia-Cortes, Miren; Medina-Caliz, Inmaculada; Hernandez, Nelia; Parana, Raymundo; Mendizabal, Manuel; Schinoni, Maria, I; Ridruejo, Ezequiel; Nunes, Vinicius; Peralta, Mirta; Santos, Genario; Anders, Margarita; Chiodi, Daniela; Tagle, Martin; Montes, Pedro; Carrera, Enrique; Arrese, Marco; Isabel Lizarzabal, M.; Alvarez-Alvarez, Ismael; Caballano-Infantes, Estefania; Niu, Hao; Pinazo, Jose; Cabello, Maria R.; Isabel Lucena, M.; Andrade, Raul J.
    BACKGROUND: Herbal and dietary supplements (HDS) consumption, a growing cause of hepatotoxicity, is a common practice among Latin-American populations. Objectives: To evaluate clinical, laboratory features and outcome in HDS-hepatotoxicity included in the Latin America-Drug Induced Liver Injury (LATINDILI) Network.
  • Thumbnail Image
    Item
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America
    (2017) Mendizabal, Manuel; Haddad, Leila; Gallardo, Patricia E.; Ferrada, Alejandro; Soza, Alejandro; Adrover, Raúl; Aravena, Edmundo; Roblero, Juan P.; Prieto, Jhon; Vujacich, Claudia; Romero, Gustavo; Muñoz, Alberto; Anders, Margarita; Hernández, Nelia; Coccozella, Daniel; Gruz, Fernando; Reggiardo, María Virginia; Ruf, Andrés E.; Varón, Adriana; Cartier, Mariano; Pérez Ravier, Roberto; Ridruejo, Ezequiel; Peralta, Mirta; Poncino, Daniel; Vorobioff, Julio; Aballay Soteras, Gabriel; Silva, Marcelo
  • No Thumbnail Available
    Item
    Serious liver injury induced by Nimesulide: an international collaborative study
    (2021) Bessone, Fernando; Hernandez, Nelia; Mendizabal, Manuel; Ridruejo, Ezequiel; Gualano, Gisela; Fassio, Eduardo; Peralta, Mirta; Fainboim, Hugo; Anders, Margarita; Tanno, Hugo; Tanno, Federico; Parana, Raymundo; Medina-Caliz, Inmaculada; Robles-Diaz, Mercedes; Alvarez-Alvarez, Ismael; Niu, Hao; Stephens, Camilla; Colombato, Luis; Arrese, Marco; Reggiardo, M. Virginia; Ono, Suzane Kioko; Carrilho, Flair; Lucena, M. Isabel; Andrade, Raul J.
    Nimesulide is a non-steroidal anti-inflammatory drug still marketed in many countries. We aim to analyze the clinical phenotype, outcome, and histological features of nimesulide-induced liver injury (nimesulide-DILI). We analyzed 57 cases recruited from the Spanish and Latin American DILI registries. Causality was assessed by the RUCAM scale. Mean age of the whole case series was 59 years (86% women) with a median time to onset of 40 days. A total of 46 patients (81%) were jaundiced. Nimesulide-DILI pattern was hepatocellular in 38 (67%), mixed in 12 (21%), and cholestatic in 7 (12%) cases. Transaminases were elevated with a mean of nearly 20-fold the upper limit of normality (ULN), while alkaline phosphatase showed a twofold mean elevation above ULN. Total bilirubin showed a mean elevation of 13-fold the ULN. Liver histology was obtained in 14 cases (25%), most of them with a hepatocellular pattern. Median time to recovery was 60 days. Overall, 12 patients (21%) developed acute liver failure (ALF), five (8.8%) died, three underwent liver transplantation (5.3%), and the remaining four resolved. Latency was <= 15 days in 12 patients (21%) and one patient developed ALF within 7 days from treatment initiation. Increased total bilirubin and aspartate transaminase levels were independently associated with the development of ALF. In summary, nimesulide-DILI affects mainly women and presents typically with a hepatocellular pattern. It is associated with ALF and death in a high proportion of patients. Shorter (<= 15 days) duration of therapy does not prevent serious nimesulide hepatotoxicity, making its risk/benefit ratio clearly unfavorable.